Abstract:

ABSTRACT Peritoneal Dialysis has been a well established renal replacement therapy for ESRD patients. However, conventional glucose-based peritoneal dialysis fluids with high glucose concentrations, low pH, high osmolality, glucose degradation products, could lead to activation of various inflammatory, metabolic disorders, and progressive damage of the peritoneal membrane structurally and functionally, and have been recognized as bio-incompatible, limiting long-term use of PD. PD solutions with a neutral pH and fewer glucose degradation products are more biocompatible, but the high price impede the popularizing process. Facing the reality of current financial constraints, an approach to individualizing the prescription of biocompatible PD solutions is sensible. In this paper, we review the current knowledge and dilemma of newer PD solutions, explore how we may individualize the prescription of biocompatible PD fluid.

Key words: peritoneal dialysis fluid, biocompatibility, reasonable prescription